Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors
- 15 April 2005
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (8), 1973-1977
- https://doi.org/10.1016/j.bmcl.2005.02.076
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The use of CDK inhibitors in oncology: a pharmaceutical perspective.Cell Cycle, 2004
- N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor AgentJournal of Medicinal Chemistry, 2004
- Pharmacological inhibitors of cyclin-dependent kinasesTrends in Pharmacological Sciences, 2002
- To cycle or not to cycle: a critical decision in cancerNature Reviews Cancer, 2001
- Cyclin-Dependent KinasesChemical Reviews, 2001
- Cyclin-dependent kinase inhibitors: novel anticancer agentsExpert Opinion on Investigational Drugs, 2000
- Novel drugs targeting the cell cycleEmerging Drugs, 2000
- CDK inhibition and cancer therapyCurrent Opinion in Genetics & Development, 1999
- CYCLIN-DEPENDENT KINASES: Engines, Clocks, and MicroprocessorsAnnual Review of Cell and Developmental Biology, 1997
- Cancer Cell CyclesScience, 1996